GlassScriptPhysician profile
Druhan L Howell
NPI 1790877892
$200,890.87
in general payments reported to CMS, 2019-2025
49 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,253 · 2020: $1,903 · 2021: $22K · 2022: $42K · 2023: $34K · 2024: $46K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Honoraria: $23K · Consulting Fee: $15K · Food and Beverage: $14K · Travel and Lodging: $8,068 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,950.00 |
| Honoraria | $22,800.00 |
| Consulting Fee | $14,815.00 |
| Food and Beverage | $13,574.25 |
| Travel and Lodging | $8,068.04 |
| Education | $255.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120,704.39 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Organon LLC | $27,872.85 | 2025 | Vtama |
| Amgen INC. | $19,897.22 | 2021-2024 | Tezspire |
| Dermavant Sciences, INC. | $15,738.02 | 2024 | Tapinarof, Vtama |
| Pfizer INC. | $3,540.34 | 2019-2023 | |
| Glaxosmithkline, LLC. | $2,423.17 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $1,540.36 | 2020-2025 | Cuvitru, Glassia, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $1,507.35 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,372.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,092.74 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genentech USA, INC. | $862.14 | 2021-2025 | Xolair |
| Grifols USA, LLC | $552.27 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Csl Behring | $493.12 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Novartis Pharmaceuticals Corporation | $404.62 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $243.55 | 2023-2025 | Opsumit, Opsynvi |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $223.06 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Sanofi-Aventis U.S. LLC | $222.81 | 2019-2023 | |
| Shire North American Group INC | $161.60 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $158.80 | 2025 | Neffy |
| Optinose US, INC. | $151.34 | 2019-2024 | |
| United Therapeutics Corporation | $136.93 | 2021-2025 | Tyvaso |
| Pulmonx Corporation | $133.77 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Gilead Sciences, INC. | $122.28 | 2020-2021 | |
| Philips North America LLC | $116.13 | 2023-2024 | (Ak6) Vest Therapy |
| Galderma Laboratories, L.P. | $113.71 | 2025 | Nemluvio |
| Mylan Specialty L.P. | $96.02 | 2020-2024 | Yupelri |
| Kaleo, INC. | $92.49 | 2022-2023 | Auvi-Q |
| Chiesi USA, INC. | $92.17 | 2019-2020 | |
| Baxter Healthcare | $92.07 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $82.73 | 2025 | Ohtuvayre |
| Abbvie INC. | $80.30 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $73.82 | 2023 | Acthar |
| Vifor Pharma, INC. | $59.17 | 2024-2025 | Zemaira |
| Blueprint Medicines Corporation | $53.66 | 2024 | Ayvakit |
| Incyte Corporation | $48.84 | 2025 | Opzelura |
| Lilly USA, LLC | $41.64 | 2024-2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $40.18 | 2021-2022 | |
| Viatris Specialty LLC | $36.83 | 2025 | Yupelri |
| Electromed, INC. | $28.27 | 2019 | |
| Octapharma USA, INC. | $23.50 | 2022 | |
| Arcutis Biotherapeutics, INC. | $22.82 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $21.48 | 2022 | |
| Leo Pharma INC. | $20.01 | 2022 | |
| Adma Biomanufacturing LLC | $19.65 | 2022 | |
| Aimmune Therapeutics, INC. | $17.07 | 2021 | |
| Kedrion Biopharma, INC. | $16.60 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Inogen, INC. | $15.79 | 2022 | |
| La Jolla Pharmaceutical Company | $15.37 | 2023 | Giapreza |
| Teva Pharmaceuticals USA, INC. | $14.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Druhan Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.